Biofrontera AG
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Hermann Lbbert
- Full Time Employees
- 149
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Hemmelrather Weg 201 Leverkusen Germany 51377
- IPO Date
- Feb 14, 2018
- CIK
- 0001712641
- Website
- biofrontera.com
- Similar Companies
- Business
- Biofrontera AG is a Germany-based biopharmaceutical company specializing in the development, manufacturing, and commercialization of prescription dermatological drugs and medical cosmetics primarily for the treatment of skin diseases. The company’s core products include Ameluz®, a photoactivated drug indicated for the treatment of actinic keratosis and basal cell carcinoma; BF-RhodoLED®, a proprietary lamp series that emits red light for photodynamic therapy (PDT); and cosmeceutical products under the Belixos® brand. Biofrontera also provides complementary dermatological products such as Advantan® and Skinoren® through strategic co-promotion partnerships, notably with LEO Pharma in Germany. The company operates sales organizations in Germany, Spain, and the United Kingdom, alongside licensing agreements expanding its geographic reach. Founded in 1997 and headquartered in Leverkusen, Germany, Biofrontera targets dermatologists, clinics, and pharmacies as its principal customers within Europe and select international markets. Recent major changes include the completion of a strategic sale and restructuring agreement with its U.S. subsidiary Biofrontera Inc., whereby Biofrontera AG transferred all U.S. assets, liabilities, and rights related to Ameluz® and BF-RhodoLED®, including New Drug Applications and manufacturing contracts, to Biofrontera Inc. This transition, finalized in late 2025, has enabled Biofrontera AG to focus on optimizing and expanding its European business operations while securing a 10% equity stake in Biofrontera Inc., thereby aligning interests. Additionally, Biofrontera AG has signed new distribution agreements, including a partnership with Propharma d.o.o. for Ameluz® distribution in Croatia and Galenica AB for promoting Ovixan® in the UK. The company successfully launched an improved formulation of Ameluz® without propylene glycol to enhance safety and extend market exclusivity, and expanded its product portfolio through licensing and co-promotion collaborations such as with LEO Pharma to market well-established dermatological products in Germany. These strategic moves underscore Biofrontera AG’s repositioning towards strengthening its European market presence and streamlined operational structure. The company operates primarily in the prescription dermatology segment, offering photodynamic therapy products, medical cosmetics, and licensed dermatology treatments. Its flagship product Ameluz® remains a market leader in photodynamic therapy in Europe, with ongoing efforts to expand its approved indications and applications. Biofrontera maintains a strong R&D focus on product innovation and label expansions, supported by its proprietary nanoemulsion technology. Its operational focus spans key European countries including Germany, Spain, the UK, and Croatia, with recent efforts aimed at broader European market expansions through licensing and distribution partnerships. Biofrontera AG’s strategic evolution reflects a deliberate shift towards consolidating its core European dermatology markets and enhancing profitability through targeted partnerships, portfolio diversification, and operational efficiencies. The company continues to leverage its innovative dermatological product lines and strategic alliances to capture market share and drive growth within the competitive biopharmaceutical landscape.
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026
Why Is Biofrontera (BFRI) Stock Down Today?
BFRI Stock Earnings: Biofrontera Misses EPS, Revenue Estimates
Biofrontera AG (BFAGY) Management on Q1 2022 Results - Earnings Call Transcript
Why Biofrontera Stock Is Surging Today
Biofrontera Inc. (BFRI) CEO Erica Monaco on Q4 2021 Results - Earnings Call Transcript
5 Short Squeeze Candidates To Watch: Vinco Ventures, TSR, Biofrontera And More
Why Are Biofrontera Shares Rising Today?
Is Biofrontera Stock A Buy Or Sell? Several Catalysts In 2022
What's Going On With Biofrontera Shares Today?
Biofrontera Stock (BFRI): Why The Price Surged Today
BFRI Stock Alert: The Social Media Chatter That Has Biofrontera Booming Today
Biofrontera Shares Are Trading Higher After Benchmark Initiates Coverage
Biofrontera Is Promising, But Could Be Limited by Competition and Volatility
$20 Price Prediction Is Ambitious but Possible for Biofrontera
Biofrontera (BFRI) Stock: Why The Price Surged Today
Why Are Biofrontera Shares Surging Today?
BFRI Stock: The News That Has Biofrontera Shares Bounding Higher Today
Biofrontera's (BFRI) CEO Erica Monaco on Q3 2021 Results - Earnings Call Transcript